Bio-Rad Laboratories Q4 Earnings Preview
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BIO?
Source: seekingalpha
- Earnings Announcement Date: Bio-Rad Laboratories is set to release its Q4 earnings on February 12 after market close, with investors keenly awaiting the results to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $2.70, reflecting a 6.9% year-over-year decline, indicating potential pressure on profitability that could affect investor confidence.
- Revenue Expectations: The consensus revenue estimate is $687.71 million, representing a 3.0% year-over-year increase, suggesting some market demand despite sluggish growth, which may provide price support.
- Historical Performance: Over the past two years, Bio-Rad has beaten EPS estimates 88% of the time, but only 38% for revenue estimates, highlighting instability in the company's profitability metrics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIO
Wall Street analysts forecast BIO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 292.420
Low
340.00
Averages
340.00
High
340.00
Current: 292.420
Low
340.00
Averages
340.00
High
340.00
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Market Reaction: Bio-Rad Laboratories shares experienced a decline of 13.3% in pre-market trading following the release of their Q4 results.
- Financial Performance: The Q4 results prompted investor concerns, leading to the significant drop in share value.
See More
- Market Recovery: The S&P 500 index rose by 0.05%, the Dow Jones Industrial Average by 0.10%, and the Nasdaq 100 by 0.18% on Friday, indicating a recovery after early losses, reflecting cautious optimism among investors regarding future economic prospects.
- Inflation Data Impact: The U.S. January Consumer Price Index rose by 2.4% year-over-year, below the expected 2.5%, marking the smallest increase in seven months, which may prompt the Fed to continue cutting rates, thus providing support for the stock market and alleviating concerns over rate hikes.
- Strong Software Stock Performance: Software stocks like Crowdstrike Holdings and ServiceNow rose over 4% and 3%, respectively, lifting the broader market and indicating a rebound in investor confidence in tech stocks, particularly amid rapid advancements in AI technology.
- Metal Stocks Retreat: Reports of the Trump administration's plans to narrow tariffs on steel and aluminum products led to declines in metal companies, with Century Aluminum falling over 7%, reflecting the negative impact of policy changes on the sector.
See More
- Chipmaker Rebound: Applied Materials (AMAT) reported Q1 adjusted EPS of $2.38, surpassing the consensus of $2.21, leading to a 10% stock price increase that helped lift the broader market, indicating strong recovery potential in tech stocks.
- Inflation Data Impact: The US January CPI rose 2.4% year-over-year, below the expected 2.5%, which may prompt the Fed to continue cutting rates, with the 10-year T-note yield falling to 4.05%, providing support for the market.
- Earnings Performance: Over two-thirds of S&P 500 companies have reported earnings, with 76% exceeding expectations, and Q4 earnings growth is projected at 8.4%, demonstrating corporate resilience and restoring market confidence.
- Market Sentiment Fluctuations: Despite the overall market rise, concerns over AI persist, putting pressure on certain stocks, particularly in tech and logistics, reflecting investor caution regarding future economic prospects.
See More
- Market Pressure Intensifies: The S&P 500 index fell by 0.22% and the Nasdaq 100 by 0.23%, reflecting investor concerns about AI technologies potentially disrupting multiple sectors, leading to a depressed market sentiment and extending Thursday's sharp losses.
- Inflation Data Impact: The US January Consumer Price Index rose by 2.4% year-over-year, below the expected 2.5%, marking the smallest increase in seven months, which drove the 10-year Treasury yield down to a 2.25-month low of 4.05%, potentially prompting the Fed to continue cutting rates.
- Earnings Optimism: Over two-thirds of S&P 500 companies have reported earnings, with 76% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings.
- Tech Stocks Underperform: The so-called
See More
- Revenue Shortfall: Pinterest reported Q4 revenue of $1.32 billion, falling short of analyst expectations of $1.33 billion, indicating competitive pressures that may undermine future investor confidence.
- Earnings Miss: The company posted adjusted earnings of 67 cents per share, below the anticipated 69 cents, reflecting challenges in profitability that could lead to shareholder scrutiny of management.
- Significant Stock Decline: Pinterest shares plummeted 19.5% to $14.95 in pre-market trading, a drastic move that may raise concerns about the company's future performance and influence investor decisions.
- Mixed Market Sentiment: U.S. stock futures showed mixed results, with Dow futures down about 0.2%, reflecting cautious market sentiment potentially linked to Pinterest's earnings report, further exacerbating investor unease.
See More

- Rivian Automotive Performance: Rivian Automotive Inc. Cl A (RIVN) saw a significant increase of 20.4% in pre-market trading.
- Roku Inc. Performance: Roku Inc. Cl A (ROKU) experienced a rise of 15.3% in pre-market trading.
- Market Context: The U.S. stock markets are set to open in two hours, indicating potential volatility.
- Investor Sentiment: The pre-market gains for both companies suggest positive investor sentiment ahead of the market opening.
See More










